Therapeutic Evaluation of Synthetic Peucedanocoumarin III in an Animal Model of Parkinson’s Disease
Sangwoo Ham(Samsung (South Korea)), Yunjong Lee(Sungkyunkwan University), Han‐Joo Maeng(Gachon University), Hyojung Kim(Samsung (South Korea)), Heejeong Kim(Samsung Medical Center), Jeong‐Yun Choi(Sungkyunkwan University), Seung‐Mann Paek(Gyeongsang National University), Jin‐Ha Yoon(Yonsei University), Yun‐Song Lee(Daegu Gyeongbuk Institute of Science and Technology), Bo Song(Northwestern University)
Cited by 7
Related Papers
Block of A1 astrocyte conversion by microglia is neuroprotective in models of Parkinson’s disease
|Nature Medicine|2018|1.2k
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
|Cell|2011|951
Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function
|Proceedings of the National Academy of Sciences|2010|282
Iduna is a poly(ADP-ribose) (PAR)-dependent E3 ubiquitin ligase that regulates DNA damage
|Proceedings of the National Academy of Sciences|2011|263
Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration
|Proceedings of the National Academy of Sciences|2015|259